狂犬病毒PM株在人用狂犬病疫苗中的研究及应用回顾  

Development and application of Pitman Moore strain in human rabies vaccine

作　　者：石磊泰(综述)[1] 李玉华(审校)[1] 俞永新(审校)[1] SHI Lei-tai;LI Yu-hua;YU Yong-xin(Division of Arboviral Vaccines,National Institutes for Food and Drug Control,Bejing 102629,China)

机构地区：[1]中国食品药品检定研究院虫媒病毒疫苗室,北京102629

出　　处：《微生物学免疫学进展》2022年第5期53-59,共7页Progress In Microbiology and Immunology

基　　金：国家科技重大专项(2018ZX09101001-002)。

摘　　要：PM株源于1882年巴斯德最初分离的狂犬病毒,经兔脑传代保存后,又历经人二倍体细胞、原代犬肾细胞、禽胚/细胞及Vero细胞等多种细胞适应传代,目前普遍应用的是人二倍体细胞适应株和Vero细胞适应株。PM株于2005年被WHO生物标准化专家委员会纳入人用狂犬病疫苗生产用毒种库,在法国、美国、伊朗、瑞士、德国、印度和中国等100多个国家和地区用于生产人用狂犬病疫苗,为全球狂犬病疫情防控发挥了积极作用。现仅就狂犬病毒PM株的由来、适应和应用作一回顾。Pitman Moore(PM) strain is believed to originate from the original rabies virus isolated by Louis Pasteur in 1882, and then inoculated and passaged in rabbit brain. After adaptation to human diploid cells(HDCs), primary dog kidney cells, duck embryos, chicken embryo cells and Vero cells, PM rabies vaccine strain is now widely cultured in HDCs and Vero cells. In 2005, PM strain was added to the human rabies vaccine production seed bank by the WHO Expert Committee on Biological Standardization(ESBC). It has been used in more than 100 countries and regions such as France, the United States, Iran, Switzerland, Germany, India and China to produce human rabies vaccine, which has played a positive role in the prevention and control of rabies epidemic all over the world. In this paper, the origin, adaption and application of PM rabies vaccine strain are reviewed.

关 键 词：狂犬病毒 PM株 人二倍体细胞 原代犬肾细胞 禽胚/细胞 VERO细胞 人用狂犬病疫苗 

分 类 号：R373.9[医药卫生—病原生物学]